Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00114218 · OUTCOME

Incidence of Adverse Effects That Are Grade 3 or Greater as Assessed by Common Terminology Criteria for Adverse Events Version 3.0

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-01-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Assessed every 28 days (28 days=1 cycle) while on study treatment, 30 days after the last cycle of treatment, and up to 5 years in follow-up

What was measured

Count of participants with Toxicities maximum grade greater than or equal to grade 3

Analysis population: Eligible and Treated patients

Groups in this outcome

Treatment (Gemcitabine Hydrochloride, Docetaxel)

Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Gemcitabine Hydrochloride: Given IV Docetaxel: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Gemcitabine Hydrochloride, Docetaxel)24

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Gemcitabine Hydrochloride, Docetaxel)18Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        18
denoms
  1. counts
    1. group Id
      OG000
      value
      24
    units
    Participants
description
Count of participants with Toxicities maximum grade greater than or equal to grade 3
groups
  1. description
    Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Gemcitabine Hydrochloride: Given IV Docetaxel: Given IV
    id
    OG000
    title
    Treatment (Gemcitabine Hydrochloride, Docetaxel)
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible and Treated patients
reporting Status
POSTED
time Frame
Assessed every 28 days (28 days=1 cycle) while on study treatment, 30 days after the last cycle of treatment, and up to 5 years in follow-up
title
Incidence of Adverse Effects That Are Grade 3 or Greater as Assessed by Common Terminology Criteria for Adverse Events Version 3.0
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice